Trial Profile
A Phase I, Open-Label, Multi-Centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML).
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Barasertib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Mar 2011 Planned End Date changed from 1 Feb 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 06 Oct 2010 New source identified and integrated (M.D. Anderson Cancer Center, 2009-0172).